Sacré, A. et al. 2016. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. Acta Oncologica. 55, 3 (Mar. 2016), 329–340. DOI:https://doi.org/10.3109/0284186X.2015.1099731.